



European
Commission

JRC PORTFOLIO 29

TACKLING CANCER AND OTHER NON-COMMUNICABLE DISEASES

Non-communicable diseases (NCDs) are the leading causes of morbidity and mortality in the European Union (EU) and worldwide. Beyond the personal and emotional strain they put on patients, families, loved ones and carers, these diseases place a massive burden on health and social systems, drain governmental budgets, reduce workforce productivity, and hamper economic growth. To a significant extent they are preventable, and preventive and mitigating action can be taken to reduce their human and financial burden.

The portfolio aims to:

Provide evidence-based approaches to the prevention, screening, diagnosis, treatment and care of NCDs, including links to health determinants

Support the development of knowledge and expertise on cancer, rare diseases and other NCDs, and the raising of standards of prevention and care in the EU

Help Member States to develop the benefits of nuclear applications in medicine, to dismantle illicit trade of products that are harmful to health, such as psychoactive substances and counterfeit tobacco

Joint
Research
Centre

Delivering on anticipation, integration and impact of EU policies:

- ▶ supporting policies and monitoring of cancer and other non-communicable and rare diseases, and developing guidelines and requirements/indicators, systems and portals that help to raise standards, thereby reducing inequalities and disparities in cancer prevention and care in the EU,
- ▶ developing methods to produce radionuclides for medicine, securing their supply and standardising protocols for the synthesis and quality control of radiopharmaceuticals,
- ▶ supporting Member States to advance activities to connect and unleash the potential of nuclear applications in medicine, such as screening, treatment, and care for cancer,
- ▶ developing certified in-vitro diagnostic reference materials for non-communicable diseases, including standardisation support on Faecal Immunochemical Testing for colorectal cancer screening,
- ▶ helping Member States to dismantle the illicit trade of products that are harmful to health such as psychoactive substances and counterfeit tobacco.

Time frame:

This portfolio has a **long-term perspective**. The Europe's Beating Cancer Plan, supported by this portfolio, sets ambitious goals to improve cancer prevention and care in Europe by 2025. The EU Knowledge Centre on Cancer aims to support both **current initiatives** (such as the Strategic Agenda for Medical Ionising Radiation Applications) to reach their objectives, but also to help, **in the long term**, to increase the EU's capacities and systems for prevention, early detection, treatment and care.

Main partners:

Partner DGs

AGRI, CNECT, COMP, EAC, EMPL, ENER, ENV, ESTAT, GROW, HERA, HOME, JUST, MOVE, OLAF, REFORM, RTD, SANTE, TAXUD

Selected stakeholders

CERN, ECHA, EEA, EMA, ESA, EMCDDA, IAEA, WHO-IARC

Non-communicable diseases

Cancer

Rare diseases

Radionuclides (radioisotopes)

Radiopharmaceuticals

Harmonisation

Health policies

Prevention

Screening

Diagnostic

Treatment

Care

Quality assurance

Health determinants

Drug and tobacco

Illicit trafficking

Nuclear medicine

Find out more



TACKLING CANCER AND OTHER NON-COMMUNICABLE DISEASES

<https://joint-research-centre.ec.europa.eu/jrc-research-portfolios/cancer-and-non-communicable-diseases>

Science for policy

Joint Research Centre

joint-research-centre.ec.europa.eu

The Joint Research Centre provides independent, evidence-based knowledge and science, supporting EU policies to positively impact society.

@EU_ScienceHub

@EU_ScienceHub

@EU_Science

EU Science, Research and Innovation

EU Science Hub - Joint Research Centre

PRINT
PDF

ISBN 978-92-76-99521-0
ISBN 978-92-76-99520-3

doi:10.2760/060187
doi:10.2760/621033

KJ-04-23-229-EN-C
KJ-04-23-229-EN-N